Evidence map›Paper›PMID 36157862›Full record

ArticleWorld journal of hepatology2022

Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma.

Nika De Wilde, Luisa Vonghia, Sven Francque, Thomas De Somer, Ali Bagdadi, Eva Staub, Jasper Lambrechts, Ana-Maria Bucalau, Gontran Verset, Christophe Van Steenkiste

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nika De WildeDepartment of Internal Medicine, University Hospital Ghent, Ghent 9000, Belgium.
Luisa VonghiaDepartment of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp 2650, Belgium.
Sven FrancqueDepartment of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp 2650, Belgium.
Thomas De SomerDepartment of Gastroenterology and Hepatology, Maria Middelares Hospital, Ghent 9000, Belgium.
Ali BagdadiDepartment of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp 2650, Belgium.
Eva StaubDepartment of Psychiatry, Université Libre de Bruxelles, Brussels 1050, Belgium.
Jasper LambrechtsDepartment of Orthopedics, University of Ghent, Ghent 9000, Belgium.
Ana-Maria BucalauDepartment of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, Université Libre de Bruxelles, Brussels 1070, Belgium.
Gontran VersetDepartment of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, Université Libre de Bruxelles, Brussels 1070, Belgium. gontran.verset@erasme.ulb.ac.be.
Christophe Van SteenkisteDepartment of Gastroenterology, AZ Maria Middelares, Ghent 9000, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. The landscape of the systemic treatment for advanced HCC is changing quickly, and recently, the standard of care became either atezolizumab plus bevacizumab or tremelimumab plus durvalumab in the single tremelimumab regular interval durvalumab regimen. Nivolumab monotherapy has proven to be effective sometimes for advanced HCC and could be a valuable treatment option for patients outside current treatment indications and reimbursement criteria for the standard of care. This is a particular population of interest.

aimTo evaluate the real-world effectiveness of nivolumab monotherapy in patients with advanced HCC who are not eligible for other treatment.

methodsWe conducted a retrospective, multicentric study including 29 patients with advanced HCC from 3 Belgian tertiary hospitals. All patients had had prior chemotherapy or were intolerant or ineligible for treatments. All study subjects received nivolumab 3 mg/kg in monotherapy, administered once every two weeks intravenously. Treatment continued until disease progression, severe adverse events or death. Data were retrieved from patients' medical records. The outcome parameters such as radiological response according to response evaluation criteria in solid tumors (RECIST) criteria, the biological response through the evolution of the alpha-fetoprotein (AFP) level, and clinical response considering both the Child-Pugh (CP) score and the World Health Organization (WHO) performance status (PS) were reported. A safety profile was also reported. Statistical analysis was performed using the SPSS Statistics 27 statistical software package.

resultsThe radiological overall response rate (defined as complete or partial response according to the immune RECIST and modified RECIST criteria) to nivolumab monotherapy was 24.1%. The biological overall response rate (defined as a decrease of ≥ 25% in AFP blood level) was 20.7%. Radiological and biological responses were significantly associated both with each other (

conclusionNivolumab monotherapy is a good treatment choice in frail patients with HCC who are ineligible for the standard of care or other validated systemic treatments.

Indexed as

Advanced hepatocellular carcinomaDifficult-to-treat patientsImmunotherapyNivolumabReal-life settingSystemic treatment

Identifiers

PMID36157862
PMCPMC9453466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.